CN114008074A - 针对12kda的apoe氨基末端片段的抗体 - Google Patents

针对12kda的apoe氨基末端片段的抗体 Download PDF

Info

Publication number
CN114008074A
CN114008074A CN202080045874.2A CN202080045874A CN114008074A CN 114008074 A CN114008074 A CN 114008074A CN 202080045874 A CN202080045874 A CN 202080045874A CN 114008074 A CN114008074 A CN 114008074A
Authority
CN
China
Prior art keywords
seq
antibody
cdr
apoe
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080045874.2A
Other languages
English (en)
Chinese (zh)
Inventor
C·萨林
J·法尔廷
M·埃里克森
C·莫勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioarctic AB
Original Assignee
Bioarctic AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic AB filed Critical Bioarctic AB
Publication of CN114008074A publication Critical patent/CN114008074A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080045874.2A 2019-06-28 2020-06-25 针对12kda的apoe氨基末端片段的抗体 Pending CN114008074A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183405.0 2019-06-28
EP19183405.0A EP3757125A1 (en) 2019-06-28 2019-06-28 Antibody directed against the apoe amino-terminal fragment of 12 kda
PCT/EP2020/067890 WO2020260491A2 (en) 2019-06-28 2020-06-25 New antibody

Publications (1)

Publication Number Publication Date
CN114008074A true CN114008074A (zh) 2022-02-01

Family

ID=67225987

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080045874.2A Pending CN114008074A (zh) 2019-06-28 2020-06-25 针对12kda的apoe氨基末端片段的抗体

Country Status (11)

Country Link
US (1) US20220242939A1 (https=)
EP (2) EP3757125A1 (https=)
JP (1) JP2022537736A (https=)
KR (1) KR20220029653A (https=)
CN (1) CN114008074A (https=)
AU (1) AU2020304855A1 (https=)
BR (1) BR112021025956A2 (https=)
CA (1) CA3140999A1 (https=)
IL (1) IL289271A (https=)
MX (1) MX2021016160A (https=)
WO (1) WO2020260491A2 (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101802007A (zh) * 2007-06-12 2010-08-11 Ac免疫有限公司 抗β淀粉样蛋白单克隆抗体
WO2010119704A1 (en) * 2009-04-17 2010-10-21 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
WO2011084714A2 (en) * 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
US20170218058A1 (en) * 2016-01-28 2017-08-03 Alector, LLC Anti-apoe4 antigen-binding proteins and methods of use thereof
WO2017189963A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018137705A1 (en) * 2017-01-26 2018-08-02 Zai Lab (Shanghai) Co., Ltd. Cd47 antigen binding unit and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168045A (en) * 1989-08-18 1992-12-01 The Scripps Research Institute Diagnostic systems and methods using polypeptide analogs of apolipoprotein e
JP2009092550A (ja) * 2007-10-10 2009-04-30 Japan Health Science Foundation うつ病またはうつ状態の同定方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101802007A (zh) * 2007-06-12 2010-08-11 Ac免疫有限公司 抗β淀粉样蛋白单克隆抗体
WO2010119704A1 (en) * 2009-04-17 2010-10-21 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
WO2011084714A2 (en) * 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
US20170218058A1 (en) * 2016-01-28 2017-08-03 Alector, LLC Anti-apoe4 antigen-binding proteins and methods of use thereof
WO2017189963A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018137705A1 (en) * 2017-01-26 2018-08-02 Zai Lab (Shanghai) Co., Ltd. Cd47 antigen binding unit and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAVID A. ELLIOTT等: "Isoform-specific proteolysis of apolipoprotein-E in the brain", 《NEUROBIOLOGY OF AGING》, vol. 32, 31 December 2011 (2011-12-31), pages 275 - 271 *
NICHOLAS M. BENTLEY等: "Apolipoprotein E structural requirements for the formation of SDS-stable complexes with b-amyloid-(1–40) : the role of salt bridges", 《BIOCHEM. J.》, vol. 366, 31 December 2002 (2002-12-31), pages 274 *
YUJI AIZAWA等: "Amino-terminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer’s disease-affected brains: a possible role for apolipoprotein E in Alzheimer’s disease", 《BRAIN RESEARCH》, vol. 768, 31 December 1997 (1997-12-31), pages 208 - 214, XP002337757 *

Also Published As

Publication number Publication date
AU2020304855A1 (en) 2021-12-23
EP3757125A1 (en) 2020-12-30
BR112021025956A2 (pt) 2022-02-08
IL289271A (en) 2022-02-01
US20220242939A1 (en) 2022-08-04
JP2022537736A (ja) 2022-08-29
CA3140999A1 (en) 2020-12-30
MX2021016160A (es) 2022-04-06
EP3990486A2 (en) 2022-05-04
KR20220029653A (ko) 2022-03-08
WO2020260491A2 (en) 2020-12-30
WO2020260491A3 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
AU2017204339B2 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
KR101981351B1 (ko) 타우를 인식하는 포스포특이적 항체
CN113891746B (zh) 焦谷氨酸淀粉样蛋白-β的抗体及其用途
AU2011208719B2 (en) Anticoagulant antidotes
US8486398B2 (en) Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds
JP7829171B2 (ja) ミスフォールドｔｄｐ－４３に対する抗体およびその使用方法
EP2974737B1 (en) Techniques for predicting, detecting and reducing a specific protein interference in assays involving immunoglobulin single variable domains
HK1207309A1 (en) Anti-tofacitinib antibodies and uses thereof for drug monitoring
US20150344568A1 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2021005019A1 (en) Tau epitope and binding molecules
WO2020260722A1 (en) Tau epitope and binding molecules
KR20250134612A (ko) Abetape3에 결합하는 항체
CN114008074A (zh) 针对12kda的apoe氨基末端片段的抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220201

WD01 Invention patent application deemed withdrawn after publication